Interim Statement 9M 2026

On November 5, 2026 Evotec reported interim statement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, Evotec, NOV 5, 2026, View Source [SID1234675053])

Tangram Announces Oral Presentation of TGM-148 Preclinical Data Highlighting Context-Dependent Mechanism of Action at the American Society of Hematology (ASH) 2026 Annual Meeting

On November 4, 2026 Tangram Therapeutics ("Tangram"), a company committed to unlocking transformative RNAi medicines for meaningful patient impact, reported that preclinical data from TGM-148, a novel GalOmic medicine for bleeding disorders, will be presented in an oral session at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, taking place 12–15 December 2026 in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TGM-148 silences Protein Z-dependent Protease Inhibitor (ZPI), a natural regulator of coagulation. It is designed to combine robust hemostatic efficacy with low thrombotic risk and infrequent administration (four or fewer subcutaneous doses a year) to substantially reduce the burden of prophylaxis. In preclinical proof-of-concept studies, TGM-148 demonstrated efficacy in four distinct genetic disease models, including a model of von Willebrand disease (VWD), the planned entry indication.

Tangram’s oral presentation at ASH (Free ASH Whitepaper) will highlight TGM-148’s unique, context-dependent mechanism of action. In non-human primate plasma depleted of factor VIII, modeling a deficiency that causes hemophilia A and is common in VWD, TGM-148 dose-dependently enhanced thrombin generation. In non-depleted plasma, TGM-148 had no effect on thrombin generation, consistent with ZPI’s adaptive role in regulating coagulation. In addition, TGM-148 was well tolerated up to the highest dose tested in a repeat-dose toxicology study in healthy non-human primates, supporting a wide therapeutic window. Together, these findings demonstrate TGM-148’s potential to restore hemostatic balance in people with bleeding disorders without increasing thrombotic risk.

"We are pleased to present data at ASH (Free ASH Whitepaper) showcasing TGM-148’s context-dependent mechanism of action, which was a key reason we chose to pursue this novel target. With this differentiated mechanism, and the prospect of quarterly or less frequent dosing, TGM-148 has the potential to offer effective, patient-friendly prophylaxis with a wide therapeutic window", said Alan Whitmore, BM BCh, FFPM, PhD, Chief Scientific Officer of Tangram.

"People living with bleeding disorders need more prophylactic options, and the data Tangram will be presenting highlight the potential of TGM-148 as a novel approach. I am excited to see it progress through clinical development to evaluate ZPI silencing as a viable mechanism for rebalancing hemostasis." added Robert F. Sidonio, Jr MD, MSc, Pediatric Hematologist at Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders, Emory University School of Medicine.

Presentation Details

Title: TGM-148, a Novel GalNAc-siRNA Targeting ZPI, Demonstrates Context-dependent Hemostatic Rebalancing in Cynomolgus Monkeys
Publication Number: 953
Session Name: 801. Gene Therapies: Beyond Transplant: The Expanding Role of Gene Therapy in Hematology
Session Date & Time: 14 December, 14:45-16:15
Location: MCCNO – 388-390

About TGM-148
TGM-148 is a first-on-target GalOmic GalNAc-conjugated small interfering RNA (GalNAc-siRNA) designed to selectively silence Protein Z-dependent Protease Inhibitor (ZPI) in the liver, where it is produced before circulating in the blood. Its context-dependent mechanism of action aims to enhance clotting in response to bleeding in those with bleeding disorders, while maintaining a favorable safety profile.

In preclinical studies, TGM-148 demonstrated efficacy in four genetic bleeding disorder models and was well tolerated at supratherapeutic doses in wildtype animals. Together, these findings support TGM-148’s wide therapeutic window and provide a strong rationale for its development across a broad range of bleeding disorders, with VWD selected as the first indication. By offering the potential for quarterly or less frequent subcutaneous administration, TGM-148 is also designed to lower the barriers to prophylaxis, supporting broader uptake, better outcomes, and improved quality of life for patients.

(Press release, e-Therapeutics, NOV 4, 2026, View Source [SID1234674164])

Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition

On November 4, 2026 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, reported that data from the ongoing Phase 1b clinical study of R2891, a potent and selective inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with lower-risk myelodysplastic syndrome (MDS) who are relapsed or refractory (R/R) to prior therapies will be presented in an oral session at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition on Saturday, December 12, 2026. In addition, the ASH (Free ASH Whitepaper) Annual Meeting will feature three poster presentations for TAVALISSE (fostamatinib disodium hexahydrate) in patients with immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The ASH (Free ASH Whitepaper) Annual Meeting is taking place from December 12-15, 2026, in New Orleans, Louisiana and virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Data from the dose escalation phase of the ongoing Phase 1b study of R289 in patients with relapsed or refractory lower-risk MDS was presented at an oral session at last year’s ASH (Free ASH Whitepaper)," said Alison L. Hannah, M.D., Rigel’s chief medical officer. "This year the data from our randomized dose expansion phase will also be presented at an oral session, providing an update on both efficacy, including the reduction of transfusion dependence, and safety. We continue to be encouraged by our evolving data in this heavily pretreated patient population."

Key highlights from the ASH (Free ASH Whitepaper) abstracts include:

In the ongoing Phase 1b study of R289 in patients with R/R lower-risk MDS, there were 64 patients enrolled as of July 16, 2026, including 33 patients in the dose escalation phase and 31 patients in the dose expansion phase. At the data cut off, R289 continues to be generally well tolerated in this elderly, heavily pretreated lower-risk MDS patient population, the majority of whom were considered to have high transfusion burden (HTB) disease at baseline. Updated study data as of a planned mid-November data cut will be presented in the oral session, including preliminary efficacy data from the dose expansion phase of the study.
In a retrospective real-world analysis of 90 patients with ITP receiving fostamatinib plus a thrombopoietin receptor agonist (TPO-RA), combination treatment was associated with increased platelet counts. Among 38 patients with available measurements during months 7-12, 81.6% had platelet counts ≥50 × 10³/µL, an increase from 33.3% of 90 patients at baseline. These findings support a treatment approach targeting multiple mechanisms of disease through the combination of fostamatinib and TPO-RAs.
Data from an interim analysis investigating fostamatinib in 799 patients enrolled in the ongoing post-marketing surveillance in Japan will be presented. No new safety signals were detected. Platelet counts increased within two weeks of fostamatinib initiation, with responses maintained at 12 months in a subset of patients who continued treatment and had available follow-up data.
In an open-label long-term extension study enrolling 71 patients with wAIHA that were treated with fostamatinib, durable hemoglobin responses were observed in >50% of patients during follow-up through Week 104. The long-term safety profile was consistent with the established safety profile of fostamatinib, with no new safety signals identified. Fostamatinib remains investigational in this setting.
ASH Annual Meeting abstracts may be accessed online at www.hematology.org.

Abstract Title

Lead
Author / Presenter

Presentation
Type /
Publication #

Session Title

Session
Date /
Time (CT)

R289

Dose Escalating / Dose Expansion Study of R289, a Dual IRAK 1/4 Inhibitor,
in Patients with Relapsed/Refractory (R/R) Lower Risk Myelodysplastic
Syndrome (LR-MDS)

Guillermo Garcia-Manero, MD

Oral presentation Publication #251

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Novel Therapeutic Strategies and Prognostic Stratification in MDS and MDS/MPN

Saturday, December 12, 2026
3:00pm – 3:15pm

TAVALISSE (fostamatinib disodium hexahydrate)

Platelet Responses with Combination Therapy of Fostamatinib and
Thrombopoietin Receptor Agonists in Immune Thrombocytopenia:
An Updated Real-World Analysis

David J. Kuter, MD, DPhil

Poster presentation Publication #1250

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I

Saturday, December 12, 2026
5:30pm – 7:30pm

Real-world safety, effectiveness, and predictors of responses to fostamatinib
in patients with ITP: interim analysis of a nationwide post-marketing
surveillance in Japan

Masataka Kuwana, MD

Poster presentation Publication #1252

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I

Saturday, December 12, 2026
5:30pm – 7:30pm

Hemoglobin Responses With Fostamatinib in a Long-Term Extension Trial in
Warm Autoimmune Hemolytic Anemia

David J. Kuter, MD, DPhil

Poster presentation Publication #4619

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III

Monday, December 14, 2026

6:00pm – 8:00pm

REZLIDHIA (olutasidenib)

Efficacy of Olutasidenib After Venetoclax in IDH1-Mutated Relapsed/Refractory
Acute Myeloid Leukemia: A Systematic Literature Review and Meta-Analysis

Jorge E. Cortes, MD

Publication only

#7191

N/A

N/A

About R289
R289 is a prodrug of R835, an IRAK1/4 dual inhibitor, which has been shown in preclinical studies to block inflammatory cytokine production in response to toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) family signaling. TLRs and IL-1Rs play a critical role in the innate immune response and dysregulation of these pathways can lead to various inflammatory conditions. Chronic stimulation of both these receptor systems is thought to cause the pro-inflammatory environment in the bone marrow responsible for persistent cytopenias in lower-risk MDS patients.2

About ITP
In patients with immune thrombocytopenia (ITP), the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding. Patients suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death. Current therapies for ITP include steroids, blood platelet production boosters (TPO-RAs), and splenectomy. However, not all patients respond to existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP.

About AML
Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow that affects myeloid cells, which normally develop into various types of mature blood cells. AML occurs primarily in adults and accounts for about 1 percent of all adult cancers. The American Cancer Society estimates that there will be about 22,720 new cases in the United States, most in adults, in 2026.3

Relapsed AML affects about half of all patients who, following treatment and remission, experience a return of leukemia cells in the bone marrow.4,5 Refractory AML, which affects between 10 and 40 percent of newly diagnosed patients, occurs when a patient fails to achieve remission even after intensive treatment.6 Quality of life declines for patients with each successive line of treatment for AML, and well-tolerated treatments in relapsed or refractory disease remain an unmet need.

About TAVALISSE
Indication
TAVALISSE (fostamatinib disodium hexahydrate) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Important Safety Information
Warnings and Precautions

Hypertension can occur with TAVALISSE treatment. Patients with pre-existing hypertension may be more susceptible to the hypertensive effects. Monitor blood pressure every 2 weeks until stable, then monthly, and adjust or initiate antihypertensive therapy for blood pressure control maintenance during therapy. If increased blood pressure persists, TAVALISSE interruption, reduction, or discontinuation may be required.
Elevated liver function tests (LFTs), mainly ALT and AST, can occur with TAVALISSE. Monitor LFTs monthly during treatment. If ALT or AST increase to ≥3 x upper limit of normal, manage hepatotoxicity using TAVALISSE interruption, reduction, or discontinuation.
Diarrhea occurred in 31% of patients and severe diarrhea occurred in 1% of patients treated with TAVALISSE. Monitor patients for the development of diarrhea and manage using supportive care measures early after the onset of symptoms. If diarrhea becomes severe (≥Grade 3), interrupt, reduce dose or discontinue TAVALISSE.
Neutropenia occurred in 6% of patients treated with TAVALISSE; febrile neutropenia occurred in 1% of patients. Monitor the ANC monthly and for infection during treatment. Manage toxicity with TAVALISSE interruption, reduction, or discontinuation.
TAVALISSE can cause fetal harm when administered to pregnant women. Advise pregnant women the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 1 month after the last dose. Verify pregnancy status prior to initiating TAVALISSE. It is unknown if TAVALISSE or its metabolite is present in human milk. Because of the potential for serious adverse reactions in a breastfed child, advise a lactating woman not to breastfeed during TAVALISSE treatment and for at least 1 month after the last dose.
Drug Interactions

Concomitant use of TAVALISSE with strong CYP3A4 inhibitors increases exposure to the major active metabolite of TAVALISSE (R406), which may increase the risk of adverse reactions. Monitor for toxicities that may require a reduction in TAVALISSE dose.
It is not recommended to use TAVALISSE with strong CYP3A4 inducers, as concomitant use reduces exposure to R406.
Concomitant use of TAVALISSE may increase concentrations of some CYP3A4 substrate drugs and may require a dose reduction of the CYP3A4 substrate drug.
Concomitant use of TAVALISSE may increase concentrations of BCRP substrate drugs (eg, rosuvastatin) and P-Glycoprotein (P-gp) substrate drugs (eg, digoxin), which may require a dose reduction of the BCRP and P-gp substrate drug.
Adverse Reactions

Serious adverse drug reactions in the ITP double-blind studies were febrile neutropenia, diarrhea, pneumonia, and hypertensive crisis, which occurred in 1% of TAVALISSE patients. In addition, severe adverse reactions occurred including dyspnea and hypertension (both 2%), neutropenia, arthralgia, chest pain, diarrhea, dizziness, nephrolithiasis, pain in extremity, toothache, syncope, and hypoxia (all 1%).
Common adverse reactions (≥5% and more common than placebo) from FIT-1 and FIT-2 included: diarrhea, hypertension, nausea, dizziness, ALT and AST increased, respiratory infection, rash, abdominal pain, fatigue, chest pain, and neutropenia.
Click here for Important Safety Information and Full Prescribing Information.

About REZLIDHIA

INDICATION
REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

IMPORTANT SAFETY INFORMATION

WARNING: DIFFERENTIATION SYNDROME

Differentiation syndrome, which can be fatal, can occur with REZLIDHIA treatment. Symptoms may include
dyspnea, pulmonary infiltrates/pleuropericardial effusion, kidney injury, hypotension, fever, and weight gain.
If differentiation syndrome is suspected, withhold REZLIDHIA and initiate treatment with corticosteroids and
hemodynamic monitoring until symptom resolution.

WARNINGS AND PRECAUTIONS

Differentiation Syndrome
REZLIDHIA can cause differentiation syndrome. In the clinical trial of REZLIDHIA in patients with relapsed or refractory AML, differentiation syndrome occurred in 16% of patients, with grade 3 or 4 differentiation syndrome occurring in 8% of patients treated, and fatalities in 1% of patients. Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening or fatal. Symptoms of differentiation syndrome in patients treated with REZLIDHIA included leukocytosis, dyspnea, pulmonary infiltrates/pleuropericardial effusion, kidney injury, fever, edema, pyrexia, and weight gain. Of the 25 patients who experienced differentiation syndrome, 19 (76%) recovered after treatment or after dose interruption of REZLIDHIA. Differentiation syndrome occurred as early as 1 day and up to 18 months after REZLIDHIA initiation and has been observed with or without concomitant leukocytosis.

If differentiation syndrome is suspected, temporarily withhold REZLIDHIA and initiate systemic corticosteroids (e.g., dexamethasone 10 mg IV every 12 hours) for a minimum of 3 days and until resolution of signs and symptoms. If concomitant leukocytosis is observed, initiate treatment with hydroxyurea, as clinically indicated. Taper corticosteroids and hydroxyurea after resolution of symptoms. Differentiation syndrome may recur with premature discontinuation of corticosteroids and/or hydroxyurea treatment. Institute supportive measures and hemodynamic monitoring until improvement; withhold dose of REZLIDHIA and consider dose reduction based on recurrence.

Hepatotoxicity
REZLIDHIA can cause hepatotoxicity, presenting as increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased blood alkaline phosphatase, and/or elevated bilirubin. Of 153 patients with relapsed or refractory AML who received REZLIDHIA, hepatotoxicity occurred in 23% of patients; 13% experienced grade 3 or 4 hepatotoxicity. One patient treated with REZLIDHIA in combination with azacitidine in the clinical trial, a combination for which REZLIDHIA is not indicated, died from complications of drug-induced liver injury. The median time to onset of hepatotoxicity in patients with relapsed or refractory AML treated with REZLIDHIA was 1.2 months (range: 1 day to 17.5 months) after REZLIDHIA initiation, and the median time to resolution was 12 days (range: 1 day to 17 months). The most common hepatotoxicities were elevations of ALT, AST, blood alkaline phosphatase, and blood bilirubin.

Monitor patients frequently for clinical symptoms of hepatic dysfunction such as fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. Obtain baseline liver function tests prior to initiation of REZLIDHIA, at least once weekly for the first two months, once every other week for the third month, once in the fourth month, and once every other month for the duration of therapy. If hepatic dysfunction occurs, withhold, reduce, or permanently discontinue REZLIDHIA based on recurrence/severity.

ADVERSE REACTIONS
The most common (≥20%) adverse reactions, including laboratory abnormalities, were aspartate aminotransferase increased, alanine aminotransferase increased, potassium decreased, sodium decreased, alkaline phosphatase increased, nausea, creatinine increased, fatigue/malaise, arthralgia, constipation, lymphocytes increased, bilirubin increased, leukocytosis, uric acid increased, dyspnea, pyrexia, rash, lipase increased, mucositis, diarrhea and transaminitis.

DRUG INTERACTIONS

Avoid concomitant use of REZLIDHIA with strong or moderate CYP3A inducers.
Avoid concomitant use of REZLIDHIA with sensitive CYP3A substrates unless otherwise instructed in the substrates prescribing information. If concomitant use is unavoidable, monitor patients for loss of therapeutic effect of these drugs.
LACTATION
Advise women not to breastfeed during treatment with REZLIDHIA and for 2 weeks after the last dose.

GERIATRIC USE
No overall differences in effectiveness were observed between patients 65 years and older and younger patients. Compared to patients younger than 65 years of age, an increase in incidence of hepatotoxicity and hypertension was observed in patients ≥65 years of age.

HEPATIC IMPAIRMENT
In patients with mild or moderate hepatic impairment, closely monitor for increased probability of differentiation syndrome.

Click here for Important Safety Information and Full Prescribing Information, including Boxed WARNING.

To report side effects of prescription drugs to the FDA, visit www.fda.gov/medwatch or call 1-800-FDA-1088 (800-332-1088).

TAVALISSE and REZLIDHIA are registered trademarks of Rigel Pharmaceuticals, Inc.

(Press release, Rigel, NOV 4, 2026, View Source [SID1234674180])

Sumitomo Pharma America to Present New Clinical Data on Enzomenib and Nuvisertib at the 2026 American Society of Hematology Annual Meeting

On November 4, 2026 Sumitomo Pharma America, Inc. (SMPA) reported two oral presentations and two poster presentations at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition, taking place December 12-15, 2026, in New Orleans, Louisiana. The presentations will feature new clinical data on enzomenib, an investigational oral small molecule menin inhibitor being studied in genetic subtypes of relapsed or refractory (R/R) acute leukemia (AL), and nuvisertib, an investigational oral small molecule highly selective PIM1 kinase inhibitor with added ACVR1 inhibition being evaluated in combination with momelotinib (MMB) in patients with R/R myelofibrosis (MF).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There remains a high unmet medical need for patients with R/R acute myeloid leukemia with KMT2Ar or NPM1m for targeted therapies that yield robust response rates and durable response that are well tolerated," said Jatin Shah, M.D., Chief Medical Officer, Oncology, SMPA. "In addition, new classes of therapeutics and combination strategies to potentially improve upon the activity of JAK inhibitors are important in MF. With this in mind, we look forward to sharing encouraging new data that further support the therapeutic potential and development of our late-stage oncology pipeline at ASH (Free ASH Whitepaper)."

For enzomenib, the oral presentation will report efficacy and safety data from the pivotal Phase 2 arm of the Horizen-1 study in patients with R/R KMT2A rearrangements (KMT2Ar) AL. The data will highlight the therapeutic potential of enzomenib as a targeted treatment option for patients with this high-risk subset of AL.

Additionally, a poster presentation will include clinical findings from the completed dose optimization study of enzomenib that informed the recommended Phase 2 dose (RP2D) in patients with R/R AL with NPM1 mutation (NPM1m). The data demonstrated that both 200 mg twice a day (BID) and 300 mg BID of enzomenib were generally well tolerated with measurable clinical activity. Objective response rates (ORRs) were 54% and 57% in patients receiving 200 and 300 mg BID, respectively, while the complete remission and complete remission with partial hematologic recovery (CR+CRh) rates were 35% at 200 mg BID and 43% at 300 mg BID.

For nuvisertib, the oral presentation will report preliminary findings from the ongoing global Phase 1 dose escalation study evaluating nuvisertib and MMB in patients with MF previously treated with a JAK inhibitor show the combination appeared to be well tolerated in the dose levels evaluated. Promising clinical activity included symptom and spleen responses, anemia improvement, and cytokine modulation. These emerging clinical data support the Phase 3 clinical development of nuvisertib in combination with MMB for patients with MF and anemia.

Presentation Details

Title

Details

Presenting Author

Investigational PIM1 kinase inhibitor nuvisertib in combination with momelotinib showed promising clinical activity in patients with myelofibrosis and anemia: Preliminary data from an ongoing Phase 1/2 study

Oral Presentation

Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Combining Forces Against Myelofibrosis

Sunday, December 13, 2026

9:30—11 a.m. CST

Presentation Time: 9:45—10 a.m. CST

Room: R02-R05 (New Orleans Ernest N. Morial Convention Center)

Lindsay A.M. Rein, M.D.

Selective PIM1 inhibition with nuvisertib promotes megakaryocyte maturation and platelet production in myelofibrosis patients

Poster Presentation

Session: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I

Saturday, December 12, 2026

5:30—7:30 p.m. CST

Room: Hall F (New Orleans Ernest N. Morial Convention Center)

Lilian Varricchio, Ph.D.

Initial report of the Phase 2 pivotal data in patients with relapsed or refractory KMT2Ar acute leukemia from the phase 1/2 trial of the investigational menin inhibitor enzomenib (DSP-5336)

Oral Presentation

Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies – Novel Combinations with Menin, FLT3 and BCL2 Inhibitors

Sunday, December 13, 2026

4:30—6 p.m. CST

Presentation Time: 5—5:15 p.m. CST

Room: Hall B (New Orleans Ernest N. Morial Convention Center)

Harry P. Erba, M.D., Ph.D.

Enzomenib dose optimization and determination of the recommended Phase 2 dose in patients (pts) with relapsed or refractory NPM1m acute leukemia

Poster Presentation

Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III

Monday, December 14, 2026

6—8 p.m. CST

Presentation Time: 6—8 p.m. CST

Room: Hall F (New Orleans Ernest N. Morial Convention Center)

Cristina Papayannidis, M.D., Ph.D.

About Enzomenib (DSP-5336)
Enzomenib is an investigational, oral, small molecule inhibitor of the menin and lysine (K)-specific methyltransferase 2A (KMT2A) protein interaction, a key interaction in acute leukemia and other tumor cell proliferation and growth.1 Menin is a scaffold nuclear protein that plays key roles in gene expression and protein interactions involved in many biological pathways, including cell growth, cell cycle, genomic stability, and hematopoiesis.2,3 In preclinical studies, enzomenib has shown selective growth inhibition in human acute leukemia cell lines with KMT2A rearrangements or NPM1 mutations.4 Enzomenib reduced the expression of the leukemia-associated genes HOXA9 and MEIS1 and increased the expression of the differentiation gene CD11b in human acute leukemia cell lines with KMT2A rearrangements or NPM1 mutations.1,4 The safety and efficacy of enzomenib are currently being clinically evaluated in a Phase 1/2 dose-escalation/dose-expansion study in patients with relapsed or refractory acute leukemia (NCT04988555) and the registrational Phase 2 Horizen-1 R/R mono AML/ALL (KMT2Ar + NPM1m) study. The FDA granted Orphan Drug Designation for enzomenib for the indication of acute myeloid leukemia in June 2022 and the indication of acute lymphoblastic leukemia in July 2026. The FDA granted Fast Track Designation for enzomenib for the indication of relapsed or refractory acute myeloid leukemia with KMT2Ar or NPM1m in June 2024 and Breakthrough Therapy Designation for the treatment of patients with relapsed/refractory acute leukemia with KMT2Ar in October 2026. Japan’s Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation for enzomenib for the indication of relapsed or refractory acute myeloid leukemia with KMT2Ar or NPM1m in September 2024.

About Nuvisertib (TP-3654)
Nuvisertib is an oral investigational selective inhibitor of PIM1 kinase with added ACVR1 inhibition, which has shown potential antitumor and antifibrotic activity through multiple pathways, including induction of apoptosis in preclinical models.5-7 Nuvisertib was observed to inhibit proliferation and increase apoptosis in murine and human hematopoietic cells expressing the clinically relevant JAK2 V617F mutation.6 Nuvisertib alone and in combination with ruxolitinib showed reduction of spleen size and bone marrow fibrosis in JAK2 V617F and MPLW515L murine models of myelofibrosis.6 In addition to its primary activity against PIM1, nuvisertib has been shown to bind and inhibit ACVR1 in preclinical studies, which may contribute to hemoglobin responses in patients with myelofibrosis.7 The safety and efficacy of nuvisertib monotherapy or in combination with a JAK inhibitor are currently being clinically evaluated in a Phase 1/2 study in patients with intermediate- and high-risk myelofibrosis (NCT04176198). The FDA granted Orphan Drug Designation to nuvisertib for the indication of myelofibrosis in May 2022. The Japan Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation to nuvisertib for the treatment of myelofibrosis in November 2024. The European Medicines Agency (EMA) granted Orphan Drug Designation to nuvisertib for the treatment of myelofibrosis in July 2025. The FDA granted Fast Track Designation to nuvisertib for the indication of myelofibrosis in June 2025.

(Press release, Sumitomo Dainippon Pharma, NOV 4, 2026, View Source [SID1234674203])

ImmunoGenesis to Present IND-Enabling Development Progress and Therapeutic Potential of IMGS-203, a Novel STING Agonist, at SITC 2026 Annual Meeting

On November 4, 2026 ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, reported upcoming presentations describing the IND-enabling activities and therapeutic potential for IMGS-203, the company’s novel Stimulator of Interferon Genes (STING) Agonist, for the treatment of recurrent glioblastoma (GBM). These data will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting taking place from November 4-8, 2026, at the Phoenix Convention Center in Phoenix, AZ.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:

Presentation Title:

IND-enabling nonclinical development of IMGS-203, a novel STING agonist, supports first-in-human translation in glioblastoma

Abstract No.:

839

Presenter:

Akash Boda, PhD, ImmunoGenesis

Presentation Date:

Friday, November 6, 2026

Presentation Time:

12:15 – 1:45 PM MT

Location:

PCC-North Building – Lower Level Exhibition Halls 4-5-6

Oral Presentation Details:

Presentation Title:

IND-enabling nonclinical development of IMGS-203, a novel STING agonist, supports first-in-human translation in glioblastoma

Abstract No.:

839

Presenter:

Akash Boda, PhD, ImmunoGenesis

Presentation Date:

Saturday, November 7, 2026

Presentation Time:

12:53 – 1:01 PM MT

Session:

204b: Rapid Oral – Clinical 2

Location:

PCC-West Building – 300 Level – 301BC

About IMGS-203
IMGS-203 is a novel STING agonist being developed by ImmunoGenesis as a cancer immunotherapy designed to stimulate antitumor immune responses. ImmunoGenesis plans to initially advance IMGS-203 into clinical development for recurrent glioblastoma (GBM), an aggressive and difficult-to-treat brain cancer with limited therapeutic options and significant unmet medical need.

(Press release, ImmunoGenesis, NOV 4, 2026, View Source [SID1234674219])